75 results about "Transplant organ" patented technology

Detectably labeled macrophage scavenger receptor antagonists useful for the diagnosis and monitoring of various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.

An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed. The system employs a warm perfusion solution capable of supporting the metabolism of the organ or tissue thereby preserving its functional integrity. The system also monitors parameters of the circulating perfusion solution, such as pH, temperature, osmolarity, flow rate, vascular pressure and partial pressure of respiratory gases, and regulates them to insure that the organ is maintained under near-physiologic conditions. Use of the system for long-term maintenance of organs for transplantation, for resuscitation and repair of organs having sustained warm ischemic damage, as a pharmaceutical delivery system and prognosticator of posttransplantation organ function is also disclosed.

An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed that employs a warm perfusion solution capable of altering the production of nitric oxide (NO) in an organ or tissue and supporting the metabolism of the organ or tissue at normothermic temperatures. Perfusion with the solution of the invention, therefore, can be used to regulate nitric oxide production in situations where it is desirable to do so, for example, to prevent reperfusion injury. The system also monitors parameters of the circulating perfusion solution, such as pH, temperature, osmolarity, flow rate, vascular pressure and partial pressure of respiratory gases, and nitric oxide (NO) concentration and regulates them to insure that the organ is maintained under near-physiologic conditions. Use of the system for long-term maintenance of organs for transplantation, for resuscitation and repair of organs having sustained warm ischemic damage, to treat cardiovascular disorders, to prevent reperfusion injury, as a pharmaceutical delivery system and prognosticator of posttransplantation organ function is also disclosed.

The invention relates to the treatment of viral, bacterial, parasitic, proliferative diseases, neurodegenerative diseases, inflammatory diseases, immunological diseases, transplanted organ rejection, and diseases produced by intoxication with heavy metals. The invention relates to the use of specific metal chelating agents including, furoic acid, 2-thiophenecarboxylic acid and their derivatives, analogs and structurally related chemicals as pharmacological agents that can be used effectively to disrupt and inactivate specific transition metal ion containing zinc finger structural motifs in metalloproteins and specific transition metal ion containing catalytic sites in metalloproteinases, which in turn, inactivate the pathogenic virus, pathogenic prokaryotic or eukaryotic cells which produces disease conditions. The preparations can be administered topically or for systemic use. The preparations are novel wide-spectrum antibiotics which have antiviral, antiproliferative, antineoplastic, antiangiogenic, antibacterial, antiparasitic, antiinfective, and anti-inflammatory effects and can be used in the treatment and prevention of diseases such as AIDS, cancers, untoward angiogenesis, pulmonary anthrax, malaria, inflammatory responses, Alzheimer's disease and other diseases.

The invention relates to nucleic acids which encode glycosyltransferase and are useful in producing cells and organs from one species which may be used for transplantation into a recipient of another species. It also relates to the production of nucleic acids which, when present in cells of a transplanted organ, result in reduced levels of antibody recognition of the transplanted organ.

This invention is directed to novel oxamyl depeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

The invention discloses a preparation and purification method of an antibody for inhibiting a chronic rejection of a transplanted organ. The preparation and purification method comprises the following steps of: step 1, collecting a periphery blood mononuclear cell through a lymphocyte separating medium and carrying out induction culture with 20ng/ml MICA; step 2, extracting a mononuclear cell protein through a nuclear protein and cytoplasm protein extraction kit; step 3, carrying out series connection on a high performance liquid chromatography (HPLC) purification anti-MICA antibody; and step 4, identifying the anti-MICA antibody and using rMICA and WesternBlot to carry out a reverse authentication. The anti-MICA antibody prepared through the method can inhibit a genetic expression of an endogenous MICA by sealing an endogenous MICA protein, an endogenous MICA and an siRNA, and therefore, an expression effect of an MICA of a transplanted organ is blocked, namely, expressions of an MICA gene and an MICA protein in a donator organ after an organ transplantation operation are effectively reduced.

The invention relates to, among other things, a method for assessing risk of organ rejection in a patient having a transplanted organ. The method includes measuring an amount of expression of a small non-coding marker RNA in a biological sample from the patient. The method further includes comparing the measured amount of expression of the small non-coding marker RNA in the patient to a reference amount of expression of the small non-coding marker RNA. In another aspect, the invention relates to kits for assessing risk of organ rejection in a patient having a transplanted organ.

A method for the early diagnosis of breast, lung, pancreatic and colon growths and cancers as well as conditions associated with donor and recipient organ transplants, both before and after transplantation to identify and allow treatment of possible transplanted organ rejection and other disease conditions related and unrelated to the transplantation, compares the gene expression patterns from a patient's peripheral blood monocytes-lymphocyte's gene system with either the similar gene expression patterns of a normal person, or with the similar gene expression patterns of a person known to have the condition being screened for. Differences between the patient's gene expression patterns for particular genes and the normal patterns indicates the presence of the condition with the number of differences indicating the probability of the condition. Similarities between the patient's gene expression patterns for those particular genes and the patterns of a person known to have the condition indicates the presence of the condition with the number of similarities indicating the probability of the condition. Portions of the method may be performed with the use of a microfluidic machine.

Novel [1,2,4]triazolo[1,5-a]pyrimidine derivative of the general formula (1): (1) its prodrug or a pharmaceutically acceptable salt thereof, which exhibits an antigen presentation inhibiting activity and is useful as a preventive and/or therapeutic agent for immunological rejection and/or graft versus host reaction in organ/bone marrow transplant, autoimmune disease, allergic disease and/or inflammatory disease and also useful as an anticancer drug or as an immunological tolerance inducer for transplanted organ/transplanted bone marrow.

Foreign cells can be grown in fetal non-mammalian hosts for the production of transplant organs and tissues, the development of new therapeutic agents, and the production of biological factors and drugs. Tissue-specific injury to fetal host target cells is carried without substantial injury to the maternal host or foreign cells, providing an environment in which the injured tissue can be regenerated with the foreign cells.

The present invention relates to methods of administering therapeutic agents to a donor organ prior to transplant comprising circulating the therapeutic agent through the donor organ while maintaining the donor organ under ex vivo perfusion conditions, as well as methods of transplanting organs, biologically modifying a donor organ prior to transplant, and treating organ failure using the methods disclosed herein.

Disclosed herein is an RGD-enriched solubilized extracellular matrix composition derived from endothelial cell culture that can be used to modify the immunogenicity or thrombogenicity of an organ intended for transplant. The RGD-enriched solubilized extracellular matrix composition is applied to the lumen of the vasculature of the organ, thereby placing a barrier between the antigens on the lumenal surfaces of the transplanted organ and the blood of the recipient.

The use of (R)-ibuprofen methanesulfonamide is described for the preparation of medicaments for the treatment and prevention of functional injury resulting from rejection reactions of transplanted organs.

In particular, the use of non-toxic salts of (R)-ibuprofen methanesulfonamide, such as the (L)-lysine salt, is described for the prevention and the treatment of rejection reactions of transplanted kidneys.

The invention belongs to the field of medicine, and particularly relates to an application of emulsified perfluorocarbon liquid in preparation of a lung preserving fluid. The emulsified perfluorocarbon liquid has the characteristics of high oxygen carrying capability and high oxygen releasing speed; blood visible components are not contained, so that cytotoxicity and generation of oxygen free radicals are reduced; a pH value is between 7.4 and 7.6, so that cellular acidification can be prevented, and cellular damages caused by activation of protease and phosphatase in cold preservation are inhibited; the colloid osmotic pressure is 390 mmH2O, so that cellular edema can be prevented; particles are small, the oxygen carrying capability is high, the gas exchange speed is fast, the emulsified perfluorocarbon liquid can easily pass through tiny capillaries and partially blocked pulmonary arterioles, the establishment of collateral circulation is promoted, the filling and oxygen supply effects are achieved, and oxidative damages are reduced; the emulsified perfluorocarbon liquid is an inert compound and can form dense and diffused physical barriers on the surfaces of cell membranes, so that the contact of inflammatory factors with target cells is prevented. The emulsified perfluorocarbon liquid is suitable for filling and preserving important transplanting organs such as lungs and the like.

A storage solution to maintain and perfuse organs awaiting transplantation comprising (a) an isotonic balanced solution comprising a physiologically acceptable amount of potassium, mono acidic phosphate, biacidic phosphate, chloride, sodium and bicarbonate ions; (b) 50-250 mM glucose; (c) 0.2-20 mM of an alkanoyl L-carnitine or a physiologically acceptable salt thereof; (d) 1 -100 mM of L-carnitine or a physiologically acceptable salt thereof; (e) water is described. The storage solution can also include other components such as anti-oxidants and/or chelating agents.

The invention discloses a medical low-temperature operation table for transplanting human tissue and organs. The operation table comprises a work table top, a rack and a circulation box. The work table top is provided with low temperature areas. Each low temperature area comprises a metal panel on the surface, and a temperature control device. The temperature control devices are semiconductor coolers, and water pipes connected with the temperature control devices are connected to the circulation box. The work table top and the metal panels are made of stainless steel, or aviation aluminum withan oxidized surface. The work table top has three areas, the working areas on two sides are close to the lower side, the storage area close to the upper side is located between the working areas, andthe low temperature areas are respectively located in the middles of the three areas. The medical low-temperature operation table has the advantages that a high-precision cooling semiconductor technique is adopted, electronic temperature controllers are applied to automatically adjust the temperatures of the operating areas to the range of 0 DEG C to 4 DEG C, the cooling speed is high, the temperature control is accurate, and continuous use can be realized; the metabolism of the transplanted organs and tissue is well slowed down, the survival rate is increased, the shedding period is reducedor avoided, the surgical effect is achieved earlier, and low temperature operation in the whole process is truly realized.

The invention discloses use of PD-L1 and/or CTLA-4 in immunosuppression. According to the use, PD-L1/CTLA-4 cytomembrane nano-vesicles expressing the PD-L1 and the CTLA-4 are prepared, actions of thePD-L1/CTLA-4 cytomembrane nano-vesicles are researched from a cellular level and an animal experiment level, and it is discovered that the PD-L1/CTLA-4 cytomembrane nano-vesicles can be bonded to a Tcell surface suppressant acceptor PD-1, present a cell surface acceptor B7 with a competitive antigen of an activated acceptor CD28 to inhibit activation of T cells and then regulate and control immune response of an organism and inhibit immunologic rejections of the organism to transplanted organs. It is shown that the PD-L1/CTLA-4 nano-vesicle suppressant can be used for preparing preparations for inhibiting the activation of the T cells and has an application prospect.